CRPC

This page shows the latest CRPC news and features for those working in and with pharma, biotech and healthcare.

J&J puts pressure on rivals with new Erleada okay in prostate cancer

Meanwhile, Zytiga – which is only approved for metastatic CRPC – pulled in $3.5bn last year, but the start of generic competition in late 2018 was evident in a 21% slump in

Latest news

Trial backs role for Lynparza in second-line prostate cancer

subpopulation of HRRms – namely BRCA1/BRCA2 and ATM mutations – and that makes PROfound “the only positive phase 3 trial of any PARP inhibitor” in CRPC. ... AZ is also conducting a phase 3 trial (PROPEL) of Lynparza in combination with Zytiga as
Bayer bags FDA nod for early prostate cancer drug darolutamide

The FDA approved darolutamide under the Nubeqa brand name for men with non-metastatic CRPC, which is shaping up to be a hotly-contested category in prostate cancer. ... It is estimated that around 73, 000 men in the US will be diagnosed with
Bayer gains FDA priority review for prostate cancer drug

Bayer reckons that tolerability is critical in non-metastatic CRPC because patients may be on therapy for years,.
Bayer, Orion prep challenge in prostate cancer market

resistant prostate cancer (CRPC), as they prepare to take on rival therapies from Johnson &Johnson and Pfizer/Astellas. ... Bayer reckons that tolerability is critical in non-metastatic CRPC because patients may be on therapy for years,.
Merck puts prostate cancer firmly in Keytruda’s sights

KEYNOTE-365 data reported at the ASCO Genitourinary Cancers Symposium this week showed that in patients with castration-resistant prostate cancer (CRPC) Keytruda improved the efficacy of Lynparza – a PARP inhibitor ... 1 inhibitor Opdivo (nivolumab)

More from news
Approximately 1 fully matching, plus 38 partially matching documents found.

Latest Intelligence

Drug launches to watch in 2019

In patients with non-metastatic CRPC, there is a high unmet need to delay development of metastases and the progression to advanced prostate cancer. ... for approval in the US and EU for non-metastatic CRPC on the strength of MFS data from the PROSPER

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Senior Account Manager / Account Director - MedComms - London: Highly competitive salary &package

Editorial Assistants - Medical Communications agency - Cheshire: Excellent Remuneration Package

Strategic Planner, Healthcare Advertising Agency: Salary TBC

Account Director, Healthcare Communications Agency: £54, 000- £60, 000

Senior / Principal Medical Writers wanted - MedComms - Various U...: Excellent Remuneration Packages

Senior Medical Writer – Medical Communications – North West – In...: Excellent Remuneration Package

Senior Copywriter: Salary TBC

Experienced / Senior Medical Writer - Excellent Progression Oppo...: Excellent Salary and Benefits on offer

Account Director, Medical Education: Salary TBC

Senior Medical Writer: Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

eyeforpharma Marketing and Customer Innovation Europe: By Richard Springham...
The Golden Goose: Why it’s so hard for the US to curb runaway drug prices...
What is changing in cardiovascular disease care?: Paul Midgley, of Wilmington Healthcare, explores the NHS Long-term Plan’s strategy for tackling cardiovascular disease and what it means for pharma...